ABILITY-2 | AMC | |||||||
---|---|---|---|---|---|---|---|---|
Mean change | ADA (N=82) | PBO (N=80) | SMD | Guyatt's ES | ADA (N=19) | PBO (N=19) | SMD | Guyatt's ES |
ASDAS | −1.1 | −0.5 | −0.63 | −1.182 | −1.5 | −0.6 | −0.89 | −1.90 |
BASDAI | −2.1 | −1.0 | −0.50 | −0.976 | −1.9 | −0.3 | −0.73 | −1.26 |
PGA (0–100 mm VAS) | −28.0 | −16.2 | −0.47 | −1.142 | −31.0 | −5.9 | −1.12 | −1.45 |
PhGA (0–100 mm VAS) | −32.7 | −18.2 | −0.64 | −1.427 | −19.8 | −4.1 | −0.87 | −1.21 |
CRP (mg/L) | −5.76 | −2.9 | −0.18 | −0.522 | −5.7 | 4.0 | −0.53 | −0.25 |
n (%) | ADA (N=82) | PBO (N=80) | Pearson's χ2 | P-value | ADA (N=19) | PBO (N=19) | Pearson's χ2 | P-value |
PSpARC40 | 33 (41) | 16 (20) | 8.18 | 0.004 | 7 (37) | 0 (0) | 8.58 | 0.003 |
PSpARC50 | 29 (36) | 9 (11) | 13.46 | <0.001 | 7 (37) | 0 (0) | 8.58 | 0.003 |
PSpARC70 | 19 (24) | 3 (4) | 13.49 | <0.001 | 2 (11) | 0 (0) | 2.11 | 0.468 |
ASDAS Major Improvement | 13 (21) | 4 (7) | 4.7 | 0.030 | 5 (26) | 2 (11) | 1.576 | 0.209 |
ASDAS Inactive Disease | 27 (34) | 12 (15) | 7.2 | 0.007 | 8 (42) | 0 (0) | 10.13 | 0.001 |
BASDAI50 | 35 (43) | 15 (19) | 10.9 | 0.001 | 8 (42) | 1 (5) | 7.13 | 0.008 |
Observed analyses.